Overview

A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2031-03-31

Target enrollment:

Participant gender:

Summary

This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation. The study has a safety run-in period followed by a randomized period.

Phase:

PHASE2

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Bevacizumab
Folfox protocol
IFL protocol
inavolisib